Tag: product lifecycle stability

Lifecycle Management of Regional Stability Submissions

Pharmaceutical products are subject to continuous regulatory oversight, especially regarding their stability profiles. Once a product is approved, stability data must be updated, monitored, and submitted according to the requirements of regional authorities like the FDA, EMA, and ASEAN. This article outlines how to effectively manage the lifecycle of stability submissions across global markets to…

Regional Guidelines: FDA, EMA, ASEAN, TGA, Regulatory Guidelines

Using Prior Knowledge in QbD-Driven Stability Planning

In pharmaceutical development, the Quality by Design (QbD) approach emphasizes scientific understanding and proactive quality planning. One of its most powerful but often underutilized tools is the use of prior knowledge—data and insights gathered from previous development projects, products, or platforms. When integrated into stability planning, this information can drastically reduce unnecessary testing, streamline timelines,…

Pharmaceutical Quality and Practices, Quality by Design (QbD) in Stability Testing

Bridging Data Across Long-Term Studies During Product Lifecycle Changes

Bridging Data Across Long-Term Studies During Product Lifecycle Changes Strategies for Bridging Stability Data Across Long-Term Studies During Product Lifecycle Changes Throughout a pharmaceutical product’s lifecycle, changes in manufacturing site, formulation, packaging, or analytical methods are inevitable. Each of these changes poses a risk to the stability profile of the product, which must be addressed…

Intermediate and Long-Term Stability Testing, Stability Testing Types

Stability Monitoring Frequency Over 36-Month Study Period

Stability Monitoring Frequency Over 36-Month Study Period Designing a Stability Monitoring Schedule Across 36 Months: Frequency Guidelines and Regulatory Best Practices A robust pharmaceutical stability program doesn’t just hinge on the conditions of testing—it also relies heavily on the timing of sample pull points. Regulatory agencies including the FDA, EMA, and WHO expect structured, risk-based…

Intermediate and Long-Term Stability Testing, Stability Testing Types